Vinod Malhotra, MD
Cardiovascular Disease · Fountain Valley, CANPI 1366500514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AstraZeneca at 32.9% of the total. Reporting peaked in 2020 at $134 and has fallen 86.6% since, to $18 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 6 payments — averaging $68.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$134
- Smith+Nephew$125
- Johnson & Johnson$112
- Sun Pharmaceutical Industries Inc.$19
- GSK$18
Across 48 payments — averaging $32,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Ironwood Pharmaceuticals, Inc$165K
- Astrazeneca UK Limited$133K
- AstraZeneca$59K
What the payments were for
- Food & beverage$39998%
- Education$102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $134 |
| Smith+Nephew | 1 | $125 |
| Johnson & Johnson | 1 | $112 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COLLAGENASE SANTYL$125
- FARXIGA$125
- SYNFIX$112
- EXPEDIUM$112
- SKYLINE$112
How this compares
$408 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $86,379 |
| OzempicSemaglutide | 81 | $86,243 |
| JardianceEmpagliflozin | 77 | $76,004 |
| TrulicityDulaglutide | 20 | $26,870 |
| MyrbetriqMirabegron | 13 | $14,727 |
| Repatha SureclickEvolocumab | 14 | $13,340 |
| MounjaroTirzepatide | 11 | $12,835 |
| FarxigaDapagliflozin Propanediol | 14 | $11,314 |
| BrilintaTicagrelor | 21 | $10,489 |
| VascepaIcosapent Ethyl | 14 | $6,040 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,152 |
| Gabapentin | 161 | $3,098 |
| Metoprolol Succinate | 121 | $2,998 |
| Losartan Potassium | 286 | $2,827 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 138 | $2,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $134 | $21,80435 claims |
| GSKBreo Ellipta | $18 | $4,15211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fountain Valley
- Bao BuiFountain Valley$430K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.